About Adagio 

​

"Success consists of going from failure to failure without loss of enthusiasm" Winston Churchill.

​

Adagio which denotes "play slowly" in music underlines the patient capital approach we take to investments in Life Sciences. 

Life sciences product commercialisation is one of the slowest and most challenging business models due to the regulatory and capital requirements presented. 

​

Our motto is "Biology bites". Any technologies addressing aspects of human biology are inherently uncertain - the greater the novelty, the greater the risk.

 

Changing clinical practice and product adoption across medicine and healthcare is slow and tortuous. For that reason, it helps if target markets are of scale, so that even modest capture rates can yield a sizeable business opportunity. 

​​

Digital Innovation is focused on Cloud applications and AI. Simplifying process and lowering frictional costs of delivery are intrinsic to healthcare products and services which seek to displace existing practice. Incremental cost impact is a major barrier to adoption, unless clinical differentiation is such, that the value created exceeds the costs required. As government procurement and purchasing increasingly defines healthcare markets, "product-market-fit" must have affordability as the key critical success factor for adoption.  

​​​

Healthcare investing should only be undertaken by experienced and patient investors, who can tolerate risk, persevere through ambiguity and sustain interest and participation over a medium to  long term horizon. 

​​​

The financial returns can be lucrative. The emotional rewards of truly making a difference in the lives of other people, is inspiring. 

​​​

Contact dave@adagiov.com

​